BCL2 and cancer: The senescent cell eliminators ABT737 [18] and ABT263 [19] are BH3 mimetic inhibitors of antiapoptotic proteins (Bcl-xL, Bcl-2, and Bcl-w) originally developed for cancer therapy; however, the inhibition of Bcl-xL was found to have serious side effects [20].